サマリー

主な調査結果
アジア太平洋地域の創薬市場は、予測期間である2022年から2030年にかけて、CAGR7.13%を記録すると予測されています。既存の医療課題と人口密集地が、製薬会社やCROに有利な研究・臨床試験の機会を提供しています。
市場インサイト
台湾、日本、オーストラリア・ニュージーランド、インド、シンガポール、インドネシア、韓国、中国、その他のアジア太平洋地域は、アジア太平洋創薬市場の成長評価のために分析されています。日本では、製品イニシアティブと上市が市場成長に寄与しています。例えば、独立行政法人医薬品医療機器総合機構は、厚生労働省と連携し、医療・医薬品の品質、有効性、安全性を保証することで公衆衛生を守る規制機関です。また、東京医科歯科大学は、臨床データからがん治療における薬剤耐性の新しいカジュアルなメカニズムを発見するためにAI（人工知能）を活用する技術を発表しました。
インドは、ジェネリック医薬品の製造・販売において、強い足場と医薬品製造能力を有しています。インドの著名な製薬会社の複数の業界専門家は、新薬の発見と開発に優先的に取り組んでいる。また、業界のリーダーたちは研究開発能力を近代化し、強化し、発展させようとしています。また、インド医薬品監督庁（Drugs Controller General of India: DCGI）は臨床試験用の医薬品の輸入と販売を規制し、臨床試験を許可しています。さらに、政府は2020年7月、創薬プロセスの補完を目的とした同国初の国家イニシアチブを導入しました。
インドネシアでは、NA-DFC（National Agency of Drug and Food Control）がインドネシア国内の医薬品の有効性、品質、安全性を保証しています。インドネシアでは、NA-DFC（National Agency of Drug and Food Control）が、販売認可の形で医薬品の承認を与え、医薬品登録申請の審査プロセスを監督しています。このような要因が、これらの国々における市場成長の原動力となっています。
競合他社の洞察
市場には、AstraZeneca Plc、Charles River、Laboratories International Inc、Bayer AG、Eli Lilly and Companyなど、著名な企業が含まれています。
当社のレポート提供は以下の通りです。
- 市場全体に関する主要な知見の調査
- 市場力学（推進要因、抑制要因、機会、課題）の戦略的な内訳
- 全セグメント、サブセグメント、地域の3年分の過去データとともに、最低9年間の市場予測を掲載
- 市場細分化により、主要セグメントを徹底的に評価し、その市場推定値を提示
- 地域別分析。言及された地域および国別セグメントの評価とその市場占有率
- 主要な分析ポーターの5つの力分析、ベンダーランドスケープ、オポチュニティマトリックス、キーバイヤークライテリア、など。
- コンペティティブ・ランドスケープは、主要企業を要因や市場シェアなどに基づいて理論的に説明したものです。
- 企業プロファイリング。詳細な企業概要、提供する製品/サービス、SCOT分析、最近の戦略的展開など

ページTOPに戻る

目次

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. GROWING R&D FOR TACKLING SEVERAL DISEASES
3.1.2. TECHNOLOGICAL ADVANCEMENTS
3.2. KEY RESTRAINTS
3.2.1. EXTENSIVE TIME-CONSUMING PROCESS
3.2.2. HIGHLY REGULATED MARKET
3.2.3. PROJECT FEASIBILITY AND SUCCESS RATE
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON DRUG DISCOVERY MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. DRUG DISCOVERY AND DEVELOPMENT PROCESS
4.5.1. DRUG DISCOVERY AND DEVELOPMENT
4.5.2. PRECLINICAL RESEARCH
4.5.3. CLINICAL RESEARCH
4.5.4. REGULATORY AUTHORITY REVIEW
4.5.5. POST MARKET SAFETY MONITORING
4.6. REGULATORY FRAMEWORK
5. MARKET BY DRUG TYPE
5.1. SMALL MOLECULE DRUG
5.2. BIOLOGIC DRUG
6. MARKET BY SERVICE
6.1. CHEMICAL SERVICES
6.2. DRUG METABOLISM AND PHARMACOKINETICS SERVICES
6.3. BIOLOGICAL SERVICES
6.4. OTHER PHARMACEUTICAL SERVICES
7. MARKET BY END-USER
7.1. PHARMACEUTICAL COMPANIES
7.2. CONTRACT RESEARCH ORGANIZATIONS
7.3. RESEARCH INSTITUTES
7.4. OTHER END-USERS
8. MARKET BY TECHNOLOGY
8.1. HIGH THROUGHPUT SCREENING
8.2. SPECTROSCOPY
8.3. COMBINATORIAL CHEMISTRY
8.4. BIOCHIPS
8.5. PHARMACOGENOMICS AND PHARMACOGENETICS
8.6. BIOINFORMATICS
8.7. METABOLOMICS
8.8. NANOTECHNOLOGY
8.9. OTHER TECHNOLOGIES
9. GEOGRAPHICAL ANALYSIS
9.1. ASIA-PACIFIC
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. KEY GROWTH ENABLERS
9.1.3. KEY CHALLENGES
9.1.4. KEY PLAYERS
9.1.5. COUNTRY ANALYSIS
9.1.5.1. CHINA
9.1.5.2. JAPAN
9.1.5.3. INDIA
9.1.5.4. SOUTH KOREA
9.1.5.5. INDONESIA
9.1.5.6. SINGAPORE
9.1.5.7. TAIWAN
9.1.5.8. AUSTRALIA & NEW ZEALAND
9.1.5.9. REST OF ASIA-PACIFIC
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS & AGREEMENTS
10.1.4. BUSINESS EXPANSIONS & DIVESTITURES
10.2. COMPANY PROFILES
10.2.1. AGILENT TECHNOLOGIES INC
10.2.2. ASTRAZENECA PLC
10.2.3. BAYER AG
10.2.4. CHARLES RIVER LABORATORIES INTERNATIONAL INC
10.2.5. ELI LILLY AND COMPANY
10.2.6. EVOTEC SE
10.2.7. GLAXOSMITHKLINE PLC
10.2.8. ICON PLC
10.2.9. IQVIA HOLDINGS INC
10.2.10. JOHNSON & JOHNSON
10.2.11. MERCK & CO INC
10.2.12. NOVARTIS AG
10.2.13. PFIZER INC
10.2.14. ROCHE AG




LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - ASIA DRUG DISCOVERY
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 4: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY DRUG TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 5: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY SERVICE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 6: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY SERVICE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 7: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 10: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 11: ASIA-PACIFIC-PACIFIC DRUG DISCOVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 12: ASIA-PACIFIC-PACIFIC DRUG DISCOVERY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 13: LEADING PLAYERS OPERATING IN ASIA-PACIFIC-PACIFIC DRUG DISCOVERY MARKET
TABLE 14: LIST OF MERGERS & ACQUISITIONS
TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES




LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: OPPORTUNITY MATRIX
FIGURE 4: DRUG DISCOVERY AND DEVELOPMENT PROCESS
FIGURE 5: ASIA-PACIFIC DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2021
FIGURE 6: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2022-2030 (IN $ MILLION)
FIGURE 7: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2022-2030 (IN $ MILLION)
FIGURE 8: ASIA-PACIFIC DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY SERVICE, IN 2021
FIGURE 9: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 10: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 11: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 12: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 13: ASIA-PACIFIC DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
FIGURE 14: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2022-2030 (IN $ MILLION)
FIGURE 15: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS, 2022-2030 (IN $ MILLION)
FIGURE 16: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)
FIGURE 17: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY OTHER END-USERS, 2022-2030 (IN $ MILLION)
FIGURE 18: ASIA-PACIFIC DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021
FIGURE 19: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2022-2030 (IN $ MILLION)
FIGURE 20: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2022-2030 (IN $ MILLION)
FIGURE 21: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2022-2030 (IN $ MILLION)
FIGURE 22: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY BIOCHIPS, 2022-2030 (IN $ MILLION)
FIGURE 23: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2022-2030 (IN $ MILLION)
FIGURE 24: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2022-2030 (IN $ MILLION)
FIGURE 25: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY METABOLOMICS, 2022-2030 (IN $ MILLION)
FIGURE 26: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2022-2030 (IN $ MILLION)
FIGURE 27: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2022-2030 (IN $ MILLION)
FIGURE 28: ASIA-PACIFIC-PACIFIC DRUG DISCOVERY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
FIGURE 29: CHINA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 30: JAPAN DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 31: INDIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 32: SOUTH KOREA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 33: INDONESIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 34: SINGAPORE DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 35: TAIWAN DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 36: AUSTRALIA & NEW ZEALAND DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 37: REST OF ASIA-PACIFIC-PACIFIC DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)